L Guilleminault

Summary

Country: France

Publications

  1. ncbi request reprint [Alveolo-interstitial pneumonia due to Temozolamide]
    L Guilleminault
    Service de Pneumologie, CHU de Tours, Universite Francois Rabelais de Tours, France
    Rev Mal Respir 25:880-4. 2008
  2. ncbi request reprint Can exhaled nitric oxide differentiate causes of pulmonary fibrosis?
    L Guilleminault
    CHRU Tours, Service de Pneumologie et d explorations fonctionnelles respiratoires, Tours, France Université François Rabelais de Tours, CEPR, Inserm U1100 EA6305, Faculte de Medecine, Tours, France Electronic address
    Respir Med 107:1789-96. 2013
  3. doi request reprint [Tropical pneumonia: pulmonary melioidosis]
    L Guilleminault
    Service de Pneumologie, Hopital Bretonneau, CHRU de Tours, Universite Francois Rabelais, 2, boulevard Tonnelle, 37044 Tours cedex 9, France
    Rev Med Interne 31:e4-7. 2010
  4. doi request reprint Asthma unmasked with tumor necrosis factor-α-blocking drugs
    Laurent Guilleminault
    Service de pneumologie et exploration fonctionnelle respiratoire, Hopital Bretonneau, Tours, France
    Chest 140:1068-71. 2011
  5. ncbi request reprint An evaluation of a new single-use flexible bronchoscope with a large suction channel: reliability of bronchoalveolar lavage in ventilated piglets and initial clinical experience
    J Mankikian
    CHRU de Tours, Service de Reanimation Polyvalente, Tours, France
    Anaesthesia 69:701-6. 2014
  6. doi request reprint Initial characteristics and outcome of hospitalized patients with amiodarone pulmonary toxicity
    J Mankikian
    CHRU Tours, Service de Pneumologie, Tours, France
    Respir Med 108:638-46. 2014

Collaborators

  • Philippe Dieude
  • J Mankikian
  • A Guillon
  • B Cormier
  • S Ehrmann
  • D Perrotin
  • T Boulain
  • A P Jonville-Bera
  • S Marchand-Adam
  • O Favelle
  • C Barc
  • M Ferrandiere
  • P Diot
  • P F Dequin
  • T Le Fol

Detail Information

Publications6

  1. ncbi request reprint [Alveolo-interstitial pneumonia due to Temozolamide]
    L Guilleminault
    Service de Pneumologie, CHU de Tours, Universite Francois Rabelais de Tours, France
    Rev Mal Respir 25:880-4. 2008
    ..Temozolomide is an alkylating agent approved for treatment of glioblastoma in association with radiotherapy...
  2. ncbi request reprint Can exhaled nitric oxide differentiate causes of pulmonary fibrosis?
    L Guilleminault
    CHRU Tours, Service de Pneumologie et d explorations fonctionnelles respiratoires, Tours, France Université François Rabelais de Tours, CEPR, Inserm U1100 EA6305, Faculte de Medecine, Tours, France Electronic address
    Respir Med 107:1789-96. 2013
    ..The aim of the present study was to determine whether there are differences in FENO (fraction of exhaled nitric oxide) between different subtypes of fibrotic ILD...
  3. doi request reprint [Tropical pneumonia: pulmonary melioidosis]
    L Guilleminault
    Service de Pneumologie, Hopital Bretonneau, CHRU de Tours, Universite Francois Rabelais, 2, boulevard Tonnelle, 37044 Tours cedex 9, France
    Rev Med Interne 31:e4-7. 2010
    ..No relapse had occurred 18 months later...
  4. doi request reprint Asthma unmasked with tumor necrosis factor-α-blocking drugs
    Laurent Guilleminault
    Service de pneumologie et exploration fonctionnelle respiratoire, Hopital Bretonneau, Tours, France
    Chest 140:1068-71. 2011
    ..The pathophysiologic mechanisms are unknown but are probably more complex than the T helper 1/T helper 2 imbalance suggested in the literature, and further studies are required...
  5. ncbi request reprint An evaluation of a new single-use flexible bronchoscope with a large suction channel: reliability of bronchoalveolar lavage in ventilated piglets and initial clinical experience
    J Mankikian
    CHRU de Tours, Service de Reanimation Polyvalente, Tours, France
    Anaesthesia 69:701-6. 2014
    ..This encouraging preliminary evaluation demonstrates the effectiveness of this new single-use device, which may obviate the need for disinfection procedures and, thereby, eradicate a potential vector of patient cross-contamination. ..
  6. doi request reprint Initial characteristics and outcome of hospitalized patients with amiodarone pulmonary toxicity
    J Mankikian
    CHRU Tours, Service de Pneumologie, Tours, France
    Respir Med 108:638-46. 2014
    ..Amiodarone-induced pulmonary toxicity (APT) is a serious adverse event that can lead to death. The aims of our study are to determine factors associated with mortality and to describe outcome and sequelae of patients with APT...